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Abstract 
How and why did the American Civil Liberties Union (ACLU) and the Public Patent 
Foundation file a lawsuit against Myriad Genetics Corporation in 2009, challenging Myriad's 
patents on BRCA1 and BRCA2 genes?  In June 2013, the Supreme Court handed down its much-
heralded ruling in Association for Molecular Pathology v Myriad Genetics (AMP v. Myriad).  
The genesis of the case is far less well known. Personal interviews conducted with the instigators 
of the case reveal a compelling story about the process of strategically framing patent policy as 
public interest litigation. The ACLU’s initial goal was to raise public awareness about gene 
patenting.  They were not at all certain they would prevail, but believed that at least the case 
would greatly increase awareness of a perceived problem, and become the focus of public 
debate… and possibly policy change.  In interviews and background documents, the major 
players describe how the ACLU was able to build a strong coalition, and as a result, beat the 
odds. 
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I.  Association for Molecular Pathology et al. vs. Myriad Genetics, Inc., et al. 
Are human genes patentable?  These four words framed the landmark case brought 
before the Supreme Court in 2013 by the American Civil Liberties Union (ACLU) and the Public 
Patent Foundation against Myriad Genetics, Inc., the company that holds the patents on the 
BRCA1 and BRCA2 genes correlating with an increased risk of breast and ovarian cancer.  AMP 
v. Myriad challenged the validity of the generally accepted practice of gene patenting in the 
United States.  On June 13, 2013, the United States Supreme Court released its decision, 
unanimously agreeing that “a naturally occurring DNA segment is a product of nature and not 
patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not 
naturally occurring” (Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al., 
No. 12-398, U.S. 2013).  In supporting the Association for Molecular Pathology's position, the 
Supreme Court’s detailed ruling held, “In this case… Myriad did not create anything. To be sure, 
it found an important and useful gene, but separating that gene from its surrounding genetic 
material is not an act of invention” (Association for Molecular Pathology et al. v. Myriad 
Genetics, Inc. et al., No. 12-398, U.S. 2013). 
                         
II. ACLU’s Involvement 
 The case against Myriad Genetics originated in 2009 when the American Civil Liberties 
Union (ACLU) and the Public Patent Foundation filed suit in Federal District Court for Southern 
New York to overturn the patents Myriad held on the BRCA1 and BRCA2 genes.  These patents 
entitled Myriad to preclude all others from using the isolated DNA in breast cancer diagnostics, 
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research, and treatment.  In essence, by issuing these patents, the U.S. government granted 
Myriad a monopoly on the breast cancer genes.  
  Four years prior to the ACLU’s filing of the lawsuit, Tania Simoncelli, Science Advisor 
at the ACLU, brought the issue of gene patenting to the attention of ACLU senior management.  
Simoncelli’s long-standing interest in the social implications of biotechnology and emerging 
genetics led her to join the ACLU in the newly created position of Science Advisor in 2003.  
Specifically, it was her job to identify cutting edge science and technology issues (with a 
particular emphasis on genomics and life sciences) that might infringe on civil liberties, and to 
develop the supporting information and argument for ACLU participation.  Likely areas of 
interest included reproductive cloning, germline debates, designer babies, behavioral genetics, 
genetic discrimination, DNA forensics, and stem cells.  Simoncelli accepted the offer from the 
ACLU over the opportunity to earn a Ph.D. at MIT because of the excitement and challenge of 
shaping an influential organization’s position on emerging life science issues, particularly with 
respect to civil liberties and law (Simoncelli). 
The ACLU purposely crafted Simoncelli’s job description as Science Advisor so that it 
would be undefined and unstructured.  Anthony Romero, the Executive Director of the ACLU, 
created this position and sought a candidate who could look broadly on 21st Century challenges 
in emerging sciences through a civil liberties lens.  Simoncelli joined the ACLU’s Technology 
and Liberty Project initiative that seeks to ensure that civil liberties are enhanced rather than 
compromised by advances in science and technology.  Where others on the Technology and 
Liberty Project were involved with well-established and documented civil liberties issues such as 
internet privacy and profiling transportation passengers in a post-9/11 world, Simoncelli 
endeavored to find the intersection between life science and social consciousness. She began 
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organizing interdisciplinary brainstorming sessions in 2004 with legal scholars, sociologists, 
scientists, and anthropologists in order to update them on emerging life science technologies.  As 
part of this project, Simoncelli coordinated and moderated a panel on gene patenting to explore 
its civil liberties implications.  Subsequently, she organized a panel focusing on behavioral 
genetics and neuroscience.  Dan Kevles, a Yale University science historian with an interest in 
the intersection of science and society, delivered the keynote address on the history of eugenics 
in the United States.  In his closing remarks, Kevles insightfully suggested that the ACLU could 
play a meaningful role in any debate on individual rights as they relate to gene patenting 
(Simoncelli). 
A week or so before the behavioral genetics and neuroscience panel discussion with Dan 
Kevles, Simoncelli approached Chris Hansen, an ACLU litigator with over thirty years of 
experience defending the rights of individuals against the vested interests of larger private 
interests. Simoncelli had become discouraged due to the difficulty of convincing her colleagues 
at the ACLU to pay attention to science, in large part because it was a  new arena to them and 
they did not feel equipped to deal with scientific issues. Hansen asked her what issues she felt 
were meaningful and she mentioned genetic discrimination and biobanking.  She then brought up 
gene patents, asking, “Do you know that there are patents on human genes?”  Hansen countered, 
“No way!  That can’t be right! What you probably mean is that there are patents on the method 
by which genes are extracted or the methods by which genes are used in diagnostic or treatment 
purposes.”  Simoncelli insisted, “No, there are patents on genes themselves.” Hansen responded, 
“You mean to tell me the U.S. government is granting a temporary monopoly on parts of the 
human body?”  Simoncelli replied, “Well technically, there are patents on isolated DNA, but in 
effect, it’s a patent on the gene itself because you’ve got to isolate the DNA to actually use it.” 
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Hansen, reluctant to believe this could possibly be accurate, urged Simoncelli to prove it.  
Simoncelli went back to her office and sent him a few articles, one of which was a policy 
argument against gene patenting written by Lori Andrews, a law professor at the Illinois Institute 
of Technology- Chicago Kent Law School and Director of ITT’s Institute for Science, Law, and 
Technology.  An hour later, Hansen rushed back to Simoncelli’s office, exclaiming, “Oh, my 
God!  You’re right!  We have to do something to challenge this.  Who can we sue?” (Simoncelli) 
Although Chris Hansen did not specialize in patent law and had no formal education in 
the field of genetics, he embraced the issue of gene patenting and vowed to learn all he could.  
He maintained it was fundamentally wrong for the U.S. government to grant a patent over a 
piece of the human body, and thus believed the ACLU to be duty bound to challenge the law.  
Simoncelli was taken aback that Hansen was unaware genes were patentable because patents had 
been granted on gene sequences for many years. An example of an early gene patent is the 
University of California’s patent on the “isolated and purified form” of a gene that encodes the 
insulin protein, granted in 1982 (U.S. Patent 4,082,613).  Claims in U.S. patents mentioned 
sequences from some twenty percent of the genes in the human body.   The fact that Hansen was 
totally unaware of gene patenting prompted Simoncelli to realize it was likely that key ACLU 
decision makers had little or no background in genomic policy issues.  At this pivotal moment, 
Simoncelli recognized that what she was doing at the ACLU was critical in shaping the 
organization’s position on crucial issues. If Chris Hansen was not aware of something as basic as 
this, most of the other 100 or so ACLU lawyers were probably not aware of it either. It would be 
her job to remedy that (Simoncelli).  
          The ACLU defines its mandate very narrowly as protecting individual rights. A patent 
claim on a part of the human body means that no one is allowed to do research on that part of the 
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human body without the patent holder’s permission.  For example, a researcher is infringing on 
the patent if he or she possesses the BRCA1 or BRCA2 gene in an isolated form, even if it is the 
researcher’s own BRCA gene. Chris Hansen asserted it was a violation of the first amendment for 
the government to give exclusive control over a body of knowledge. Offended by the idea of 
treating human genes as personal property, he stressed that patenting on genes should be 
managed in the public interest (Hansen). 
A legal doctrine arising in Supreme Court case law states, “One cannot patent a product 
of nature, a law of nature, or an abstract idea.”  Hansen and the ACLU argued that gene 
patenting violated at least two of these three categories.  The first argument was that a gene is a 
product of nature; scientists do not create a gene, nature creates a gene.  The second argument 
was that genes are commands to the body as to what it should be doing; therefore, genes direct 
the body and a gene embodies the laws of nature (Hansen).  The ACLU contended, “Human 
genes, even when removed from the body, are still products of nature, and their associations with 
diseases are laws of nature” (ACLU Fact Sheet).  Genes are not inventions; they are naturally 
occurring parts of our bodies. 
 In 2005, Simoncelli and Hansen began working in earnest on this gene patenting project, 
spending the next three years collecting and reading literature and meeting with experts in the 
field to identify the most appropriate legal theory to pursue.  One of the first people Simoncelli 
contacted was Lori Andrews, an expert on biotechnology issues. Andrews challenged the ACLU 
to consider the civil liberties implications of gene patenting.  Dan Kevles, a Yale science 
historian, met with the ACLU and generated further interest.  The NIH’s SACGHS (Secretary’s 
Advisory Committee on Genetics, Health, and Society) released its draft report on this issue 
around this time, and Simoncelli was able to utilize this report to build additional support 
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(Simoncelli).  For the most part, the patent lawyers they met with through this exploratory 
process advised them not to pursue the case because the ACLU was “flat out wrong and they 
would lose because isolated human genes are obviously patentable” (Hansen).  On the other 
hand, scientists and geneticists encouraged the ACLU’s interest because they believed patents 
should not be granted on human genes.  However, since gene patenting had been going on for 
over twenty years at that point, many of these same scientists maintained the issue was not worth 
revisiting.  They had waged this battle years ago and lost (Hansen).  Yet, a core group of 
scientists and legal experts not only agreed that challenging gene patents was a good idea, they 
were more than willing to help by providing background knowledge and information.  Among 
the experts with whom the ACLU consulted early in its process were Dr. Bob Cook-Deegan, 
Duke University’s Director of Genome, Ethics, Law, and Policy; Dr. Arti Rai, an IP expert and 
Co-Director of Duke Law Center for Innovation and Policy; Dr. Mary-Claire King, discoverer of 
the genetic linkage between BRCA1 and risk of breast cancer, as well as other science and legal 
experts. These are the people Simoncelli and Hansen turned to for encouragement, confirmation 
of the end goal, and perspective (Simoncelli).   
Concurrent with their research and investigation, Simoncelli and Hansen began shaping 
the talking points that would eventually win over the ACLU Board of Directors to the idea of 
challenging gene patenting. Simoncelli and Hansen knew that what they were proposing might 
initially be considered outside the ACLU’s traditional civil liberties realm and that the eighty 
member board might resist the idea.  After all, Simoncelli had been hired to identify cutting edge 
science issues, and the issue of gene patenting had been around for over twenty years; there was 
nothing cutting edge about it.   More importantly, the ACLU had never engaged 
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surrounding patent law. To their surprise, the board completely supported the idea, encouraging 
them to frame the issue as an infringement on civil liberties (Simoncelli). 
The goal of Simoncelli and Hansen, and by extension, the ACLU, was to change the law 
and end gene patenting in the United States.   When first discussing this, they realized there were 
several paths they could pursue.  One option was to have the patent office re-examine certain 
patents, but any remedy would only apply to specific patents and was not going to end gene 
patenting overall.  A second option was to seek a legislative solution, but other organizations had 
tried this before without success (Simoncelli).  Congressional Representatives Xavier Becerra 
(D-CA) and Dave Weldon (R-FL) even crafted a bipartisan bill in 2007 to prohibit future human 
gene patenting, but the bill died in committee (Reynolds and Darnovsky).  
The ACLU was interested in pushing the boundaries and changing the law.  They settled 
on the judicial route because they realized they were not going to be successful through 
legislation.  Hansen was a litigator and he immediately thought, “Who can we sue” (Simoncelli)?  
Since sequences from over 4,000 genes were already patented (Cook-Deegan), including those 
associated with Alzheimer’s disease, muscular dystrophy, colon cancer, and asthma, the ACLU 
had a fairly deep pool of potential targets. 
 
III. Determining Whom to Sue 
After reviewing target candidates, the ACLU elected to challenge the patents held by 
Myriad Genetics, a molecular diagnostics company based in Salt Lake City, Utah. Myriad 
Genetics owned the patents on the BRCA1 and BRCA2 genes that correlate with an increased risk 
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for breast and ovarian cancer.  The ACLU emphasized that the general public needed to 
understand the significance of this issue. According to Chris Hansen, “It could not be seen as a 
case about genetics.  It could not be seen as a case about patent law.  It had to be seen as a case 
about public policy and health” (Hansen). The ACLU acknowledged that most would not 
understand genetics, yet nearly everyone would be familiar with breast cancer and would know 
someone personally who has been affected.  Hansen and Simoncelli briefly contemplated 
challenging the patents on long Q-T syndrome, a rare condition that causes the heart to suddenly 
stop beating (leading to sudden death), but agreed it would be too difficult to explain and people 
would not fully understand it (Simoncelli).  Long Q-T syndrome did, however, provide a 
compelling example of previous gene patents that harmed the patient population due to restricted 
access to testing (Angrist Amicus Brief to the Counsel for Amicus Curiae AARP).  However, 
breast cancer resonates much more strongly with the public because the disease has touched 
nearly everyone in some way; hence, the ACLU settled rather quickly on suing Myriad Genetics 
(Hansen).     
Another reason for choosing Myriad Genetics was that Myriad had been a “bad corporate 
citizen” (Hansen). In 1996, Myriad Genetics launched its BRACAnalysis® test for detecting 
mutations in the BRACA1 and BRACA2 genes that put women at substantially increased risk of 
developing breast and ovarian cancer.  As sole owners of the BRACA1/2 patents, Myriad kept 
other companies from offering a similar diagnostic test, effectively preventing women from 
validating test results with a second opinion.  Additional genetic mutations for susceptibility 
were discovered after Myriad obtained its patents.  However, facing no market competition, 
Myriad had little incentive to adopt new methods of testing, including methods that would not 
miss large-scale chromosome rearrangements that BRACAnalyis® missed.  This led to twelve 
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percent of women receiving false negative results (Walsh, King).   In addition, Myriad had little 
incentive to improve the quality of its data interpretation, often releasing results of “variants of 
unknown significance.”  By threatening lawsuits and strictly enforcing its monopoly, Myriad 
prohibited other laboratories from developing more accurate testing.  For a period of several 
years, the company knowingly sent incomplete results to women who were entirely dependent on 
this test to determine whether or not they should take preventive measures to safeguard their 
health (Hansen). Myriad eventually added rearrangement testing, yet did not incorporate this 
sequencing into its basis BRACAnalysis® test.  Instead, the company charged women $700 
separately for its newer BRCA Analysis Rearrangement Test (BART®).  Essentially, women 
were expected to undergo testing with the original BRACAnalysis® for $3400, and then if the 
results came back negative, they had the option of undergoing the second BART® test for $700 
(FORCE – Facing Our Risk of Cancer Empowered).  The high cost made BRCA testing 
unaffordable to many women.  Furthermore, Myriad began controversial direct-to-consumer 
television and magazine advertisements promoting breast cancer susceptibility testing to women, 
scaring women with no family history of breast or ovarian cancer into thinking they needed to be 
tested.  
 
IV. Framing the Case 
Genetics and patent law are difficult subjects for those not trained in these specialties.  
Patents contain volumes of arcane legal and technical language that the ACLU team had to wade 
through to figure out which patents to pursue. Simoncelli and geneticists walked Chris Hansen 
through the science of genetics.  They spent a significant amount of time trying to simplify.  
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They talked to numerous genetics experts who explained what a gene is, what the significance of 
a gene is, how to isolate it, and why a gene is a product of nature, and not the result of a human 
invention.   The ACLU focused in particular on the Section 101 patent requirement of a “new 
and useful composition of matter.”  This means that both the structure as well as the function of 
the isolated DNA must be “markedly different from that which occurs inside the body” (AMP v. 
Myriad). 
A critical decision that Hansen and Simoncelli made was to frame the case as a civil 
rights case rather than a patent case.  Patent cases typically involve two large competing 
corporations suing over conflicting patents or infringing patents.  They are framed narrowly. 
Such a patent case was of no interest to the ACLU, and the ACLU assumed it would be of little 
interest to the courts (Hansen).  Civil rights cases tend to be framed in broad social and ethical 
terms.  Simoncelli knew the science and could articulate all the policy arguments about what was 
wrong with gene patenting and what it meant for access to care and the future innovation of 
biomedicine.  A lot of those arguments were not legal arguments.  Hansen was an experienced 
litigator and knew how to introduce civil rights litigation.  Neither Simoncelli nor Hansen could 
have accomplished what they did without each other (Simoncelli). 
           The ACLU committed itself to putting this issue in a broader context and discussing the 
public policy harms that occurred as a result of BRCA patents (Hansen).   They wanted to make 
the larger point that this was more than just about patent law and more than just about genetics.  
For example, the ACLU included a declaration from the person in charge of assembling 
worldwide information on breast cancer genes, stating that Myriad had stopped sharing 
information with the scientific community.  Specifically, the company refused to participate in 
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the international collaborative mutaDATABASE and had not contributed to the NIH funded 
Breast Cancer Information Core since 2004 (Brody).  
According to the lawsuit, gene patenting violates civil liberties, and in particular, the First 
Amendment because patents on DNA “grant control over a body of knowledge and pure 
information” (AMP v. Myriad Genetics). Gene patents, therefore, hinder scientific progress.   As 
sole owners of the BRCA genes, Myriad had the right to perform further research on individual 
samples of women’s DNA without permission from the women. Myriad’s control over the large 
set of data collected from its BRACAnalysis® testing was legally withheld from other 
researchers with significant implications for public health and breast cancer research (Hansen). 
The lawsuit contends that gene patents violate the Constitution’s patent clause, hindering the 
authority of Congress to “promote the progress of science.”  Gene patenting stifles scientific 
advancement as “there is no way to invent around a gene” (ACLU Fact Sheet). To illustrate this 
point, Reynolds and Darnovsky argue in The American Interest, “Patents are meant to provide a 
better mousetrap, but human gene patents, in effect, claim the entire concept of catching mice” 
(Reynolds and Darnovsky).    
          The ACLU followed the same strategy in approaching the gene patenting case as it did for 
all its other cases – internet censorship cases, children’s rights cases, women’s rights cases, and 
social justice cases.  They set out to identify a group of plaintiffs to illustrate why this case was 
so meaningful.   They saw it as an issue that was vital for the future of biomedical innovation and 
for public health.  If they had framed the case more narrowly, the case probably would never 
have been chosen to be reviewed by the Supreme Court (Hansen).     
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V.  Gathering Plaintiffs 
 As the ACLU itself would have no legal standing in the case, Simoncelli and Hanson 
needed to establish early on who would sue Myriad Genetics. Simoncelli was in charge of 
plaintiff recruitment.  At first it was an uphill battle.  Even if a particular organization or 
individual seemed interested, the candidate needed to be willing to commit significant resources 
to this endeavor.  While plaintiffs did not have to commit financial resources, they did 
nonetheless have to be willing to commit a substantial amount of time to review legal briefs.   It 
was a lot to consider and it was a daunting proposition to challenge Myriad Genetics and the 
USPTO.  Furthermore, since these potential plaintiffs had not worked with the ACLU before, 
the ACLU needed to gain their trust (Simoncelli).  Another consideration was that most 
professional organizations are large membership organizations and litigation-averse. There is 
oftentimes someone in the organization who steadfastly takes the opposing side of an issue, and 
many organizations are reluctant to alienate even a minority of its members (Hansen).  
The Association for Molecular Pathology (AMP) was the first to sign onto the case and 
became the lead plaintiff.  AMP is an international non-profit professional consortium 
representing over 1,500 physicians, doctoral scientists, and medical technologists who perform 
molecular diagnostic testing. AMP joined the lawsuit because its members believed gene patents 
can “serve as a disincentive to innovation in molecular testing.”  These patents “deny access to a 
vital baseline of genomic information that cannot be ‘invented around.’ Moreover, the threat of 
enforcement from a patent holder and ensuing litigation costs lead to a chilling effect as clinical 
laboratories and manufacturers are reluctant to develop new tests that could directly benefit 
patients” (Association for Molecular Pathology plaintiff statement). Once AMP signed on, the 
ACLU built its coalition from there, finding a group of twenty plaintiffs to illustrate why this 
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case was so far-reaching. When building the coalition, the ACLU sought to represent a wide 
array of organizations, physicians, researchers, and women affected by gene patenting 
(Simoncelli). They ended up with four national organizations of geneticists representing more 
than 150,000 researchers and laboratory professionals (the Association for Molecular Pathology, 
the American College of Medical Genetics, the American Society for Clinical Pathology, and the 
College of American Pathologists); six prominent geneticists (Haig Kazazian, MD, Arupa 
Ganguly, Ph.D., Wendy Chung, MD, Ph.D., Harry Ostrer, MD., David Ledbetter, Ph.D., Stephen 
Warren, Ph.D.); two breast cancer advocacy groups (Breast Cancer Action and Boston Women’s 
Healthbook Collective); two genetic counselors (Ellen Matloff, M.S., Elsa Reich, M.S.); and six 
individual women with breast/ovarian cancer or at high risk for it (Lisbeth Ceriani, Runi Limary, 
Genae Girard, Patrice Fortune, Vicky Thomason, and Kathleen Raker)  (ACLU). The individual 
women were included, in large part because Anthony Romero, the ACLU Director, had given his 
blessing to go forward with the case, but had stipulated that they involve actual women 
(Hansen).  It was very important to him to bring this case as part of an individual right’s case 
with stories from individual women, breast cancer survivors and those intimately affected by the 
BRCA gene.  The overall group of plaintiffs asserted that its central complaint was that Myriad 
Genetics’ patents on the BRCA1 and BRCA2 gene allowed it to enjoy a monopoly over human 
DNA that is fundamental to research, medicine, and the health and well-being of patients at high 
risk for breast and ovarian cancer.   
         It turned out that adding actual patients as plaintiffs was one of the most controversial 
aspects of the case.  According to Chris Hansen, the Patent Bar and some of the courts were 
“astonishingly offended at the idea that women had a legal interest in whether these patents 
existed or not” (Hansen).  What these entities failed to understand is that access to the gene was 
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more than a legal argument; it was a matter of life and death to those who carried mutations in 
BRCA genes. With Myriad’s monopoly, the only place women could get tested was through 
Myriad’s laboratory.  Patients had to trust Myriad’s test results, they had to assume Myriad was 
testing properly, they could not get a second opinion, and the cost (that may or may not be 
covered by insurance) put the test out of financial reach to many women.  Given the limited 
information and options with this life-threatening disease, the ACLU found the notion that 
women would not have an interest in whether this was proper public policy or not “bizarre” 
(Hansen).  
          In order to recruit individual patient plaintiffs, the ACLU tapped into the resources of its 
Women’s Rights Project.  The focus on the BRCA1 and 2 patents tied into the Women’s Rights 
Project through its “shared interests in rights to women’s health, rights to bodily integrity, the 
notion of human dignity, and promoting the progress of science” (Park).   Sandra Park, its 
Director, took the lead in recruiting and identifying individual women plaintiffs. Patients’ voices 
were vital in explaining how deeply personal patents could be in their lives. Park appreciated that 
this case was decided in the Supreme Court rather than by patent law experts because it allowed 
for these voices to be heard (Park, JOLT Symposium).   In order to get in touch with women 
with an interest in BRCA testing, the Park and the Women’s Rights Project worked through 
FORCE (Facing Our Risk of Cancer Empowered), a national nonprofit organization devoted to 
improving the lives of patients and families affected by hereditary breast and ovarian cancer.  At 
first, FORCE was concerned that a successful outcome for the ACLU in its case against Myriad 
could result in a proliferation of BRCA gene tests on the market, and women would be confused 
as to which tests were accurate.  However, FORCE agreed to post a request on its list serve 
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asking women who had experience undergoing BRCA gene testing to contact the ACLU 
(Simoncelli).   
          The ACLU aimed for a variety of personal history stories, including women concerned 
they did not receive an accurate test result due to “variants of uncertain significance,” women 
who wanted a second opinion to determine if anyone had more information about their particular 
variant, and women who wanted to get tested and could not afford the high price for the test 
(Park). The ACLU knew that the women plaintiffs’ legal standing was tenuous, but felt that it 
was imperative to get these stories out because it is principally women whose lives are affected 
by this disease.  These are the women who, with a family history of breast or ovarian cancer, live 
in fear of a positive test for a BRCA gene mutation, knowing that a positive test means they will 
have up to an 87% chance of developing breast cancer in their lifetime and up to a 44% chance 
of developing ovarian cancer (Ford).  These are the “previvors” and survivors who need access 
to accurate and affordable testing to empower them to take control over their destinies should 
they receive a positive test.  Rather than wait to be cancer victims, these women have options of 
increased surveillance with mammograms, MRIs, and ultrasounds; chemotherapy drugs; or 
prophylactic bilateral mastectomies and oophorectomies (FORCE).  The case had far reaching 
consequences for these women.  
          The women’s personal stories were compelling.  One of the plaintiffs, Lisbeth Ceriani, was 
a single mother diagnosed with bilateral stage IIA breast cancer at age 42.  Ceriani’s health 
insurance, Mass Health, would cover the cost of BRCA genetic testing provided a contracted 
provider performed the test.  Myriad Genetics, the only lab in the country authorized to conduct 
BRCA testing, refused to agree to a contract with Mass Health because the proposed 
reimbursement was too low.  Ceriani was forced to save for eighteen months and pay out of her 
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own pocket to undergo BRCA testing, all the while coping with the uncertainty of her future 
health.  She learned that she did, in fact, carry a mutation (ACLU plaintiff statements). 
          Another plaintiff, an Asian-American woman named Runi Limary, was diagnosed with an 
aggressive form of breast cancer at age 28.  Her doctor recommended BRCA testing to determine 
if she was at risk for ovarian cancer and/or a second occurrence of breast cancer.  Her results 
from Myriad came back indicating her BRCA gene had a “variant of unknown significance.”  
This ambiguous result is reported disproportionately in minority women.  Limary, at 28 and with 
no children yet, struggled with reaching a decision as to whether or not to have her ovaries 
removed prophylactically.  She wanted a second opinion in hopes of improving her 
understanding of the ambiguous result before undergoing such a life-changing surgery.  Limary 
was unable to obtain a second opinion because Myriad had a monopoly on the testing (ACLU 
plaintiff statements).  
          Another woman, Genae Girard, had a double mastectomy after being diagnosed with 
breast cancer at age 36.  She tested positive for a mutation, but she wanted to have these results 
validated with a second opinion before having her ovaries removed.  She, like Runi Limary, was 
unable to confirm the results with a second opinion since Myriad exclusively conducted the 
testing (ACLU plaintiff statements).  
          Two other women plaintiffs, Kathleen Raker and Vicky Thomason, both tested negative 
with BRACAnaylsis®, but were informed they needed to pay Myriad $700 upfront for additional  
BART® testing.  Kathleen Raker’s mother died from breast cancer at the age of 28 and her 
maternal grandmother died from breast cancer at 52. She worried about having a genetic 
predisposition for cancer, but could not afford further testing. Vicky Thomason was diagnosed 
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with ovarian cancer and wanted to make a decision about prophylactic treatment if she was 
predisposed to cancer, yet the cost of the additional testing was beyond her means (ACLU 
plaintiff statements). The ACLU’s inclusion of these individual women as plaintiffs was 
purposefully designed to illustrate the fact that these patents were a life and death matter to real 
people.    
          Our Bodies Ourselves (OBOS) was one of two advocacy groups, along with Breast Cancer 
Action, that became a plaintiff in the suit. Our Bodies Ourselves is also known as the Boston 
Women’s Health Book Collective and is listed as such on the record of official plaintiffs.  Lori 
Andrews, a strong and vocal opponent of gene patenting from Chicago Kent Law School, 
recruited OBOS, and OBOS, in turn, recommended Breast Cancer Action (Norsigian).  OBOS, 
while not specifically a breast cancer advocacy group, deals with women’s health in general.  
OBOS provides information to its constituents on many issues, including breast cancer, and is 
committed to providing women with the tools for informed decision making.  One of its missions 
is “to advocate for women's health by challenging institutions and systems that block women 
from full control over their bodies” (Our Bodies Ourselves). The organization debated in the 
beginning if it would legally have standing in the case, but ultimately believed it would 
(Norsigian, Harvard STS). 
           Judy Norsigian, the Executive Director and one of the founders of OBOS, outlined at the 
Harvard Science, Technology, and Society symposium in November 2013 the reasons why her 
organization became involved in the case against Myriad.  OBOS leaders believed that Myriad’s 
patents on the BRCA genes impeded women’s control over their own healthcare by restricting 
access to information necessary to make healthcare decisions. The high cost of the Myriad 
BRACAnalysis® test troubled OBOS and the organization was aware of geneticists who could 
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perform testing for substantially less; however, these geneticists did not have the legal resources 
to engage in a lawsuit after receiving cease-and-desist letters.  Women’s inability to obtain 
second opinions also concerned the leaders of OBOS, and with that, the possibility of poor 
personal medical decisions based on lack of knowledge.  OBOS also contended that gene 
patenting undermined research.   In particular, the lack of data sharing and analysis was a cause 
for concern.  To OBOS, it did not make sense for Myriad to have the sole right to use or not use 
the information to better understand breast and ovarian cancer genetics.  In addition, OBOS was 
bothered by the limited information on breast cancer susceptibility for underserved populations.  
African Americans, Latinos, and Asian American women were disproportionately likely to 
receive ambiguous results with Myriad testing, yet these women had nowhere to go for a second 
opinion to clarify ambiguous results.  It was clear to OBOS that the protection afforded by these 
gene patents was negatively affecting women’s health (Norsigian, Harvard STS).  
           Norsigian knew of women who lived in Boston and flew to Europe to be tested with a 
more accurate analysis for less than it cost them to be tested at home.  Others did the same, not 
for cost savings, but for a second opinion.  The economics had become skewed because 
European health care systems, operating within the fixed budgets of universal health care 
coverage, found themselves similarly in a bind with respect to the cost of Myriad testing.  These 
countries could not afford to offer testing for all women at risk.  In May of 2004, the European 
Patent Office revoked Myriad’s patents after ruling that, while Myriad had figured out the key 
genes involved with a higher risk of breast and ovarian cancer, it had done nothing to meet the 
“inventiveness” standard required of a patent.  The company had simply discovered something 
that already exists in nature.  Faced with a similar health care dilemma, the Canadian 
government announced that the province of Ontario would simply ignore the Myriad patents and 
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conduct its own BRCA testing at publicly funded labs.  With this alternative testing, Canadians 
received BRCA test results much sooner than they did with Myriad, and at one third the cost.  
Acting on Myriad’s behalf, the U.S. Ambassador to Canada responded by threatening trade 
sanctions.  All of these reasons convinced Our Bodies Ourselves of the validity of the case and 
the organization’s leaders wrote opinion pieces to generate interest among the public in this 
lawsuit (Norsigian, Harvard STS).  
           Dr. Wendy Chung, M.D., Ph.D., a clinical and molecular geneticist and director of 
Clinical Genetics at Columbia University, enthusiastically joined the case as a plaintiff 
(Simoncelli).  Chung believes that gene patenting compromises both access to and quality of care 
that patients receive.  Since Myriad Genetics had exclusive rights for BRCA genetic testing, the 
lack of competition stifled opportunities for improvements in both the test and in its data 
interpretation.  Chung also expressed dissatisfaction with Myriad’s unnecessarily slow 
turnaround time for testing.  In addition, exclusivity allowed Myriad to charge excessively high 
prices that often put testing out of reach of many women.  From the time Myriad developed the 
test in 1996 through 2003, many insurers did not cover BRCA testing, or the lengthy 
preauthorization processes discouraged patients from pursuing coverage.  Some of Dr. Chung’s 
patients died during the preauthorization process, leaving family members with no genetic 
information to guide the future care of other relatives.  Medicare did not cover the cost of testing 
until 2003.  Medicaid did not begin to cover the cost until 2005, and at the time the case went to 
the Supreme Court, Medicaid still did not cover the cost in many states (ACLU plaintiff 
statements).  
           Dr. Harry Ostrer, a Professor of Pediatrics, Pathology and Genetics at the Albert Einstein 
College of Medicine of Yeshiva University and Montefiore is another medical researcher who 
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joined the case as a plaintiff.  He formerly served as Professor of Pediatrics, Pathology, and 
Medicine and Director of the Human Genetics Program at New York University School of 
Medicine.  Dr. Ostrer oversaw the genetic risk assessment program at NYU Langone Medical 
Center (NYULMC) as well as New York’s Bellevue Hospital. When Tania Simoncelli first 
approached Dr. Ostrer about becoming involved in the case, he indicated he was not interested.  
However, something Simoncelli said persuaded him, and he mulled the decision over in his mind 
for several weeks before contacting her again. He was convinced “gene patents were stifling 
innovation” (Simoncelli). There had been no innovation, for example, in breast cancer genetic 
testing in the previous five years since Myriad Genetics had introduced its most recent test.  
Gene patents presented significant hurdles to Ostrer’s work and many of his high-risk patients at 
Bellevue Hospital could not afford BRACAnalysis®.  He also noted that frequent test results of 
“variants of unknown significance” were confusing to both patients and physicians, leaving them 
unsure as to whether or not they were at increased risk of developing cancer.  At one point Dr. 
Ostrer suggested a collaborative study with Myriad to help clear the confusion on “variants of 
unknown significance,” but Myriad was not open to collaboration (ACLU plaintiff statements).    
          Dr. Arupa Ganguly, a geneticist and clinical pathologist, was the Co-Director of the 
Genetic Diagnostic Laboratory at the University of Pennsylvania and joined the lawsuit because 
the legalities of patents block critical research. She had been offering breast cancer susceptibility 
testing with a different and less expensive test than Myriad’s test.  Her clinic did not charge 
Myriad’s rates in part because health insurance would not reimburse at those rates. Myriad 
aggressively enforced its patents to create exclusivity, and Dr. Ganguly and the University of 
Pennsylvania’s Genetic Diagnostic Laboratory received a threatening cease-and-desist letter 
from Myriad on the basis of patent infringement (ACLU plaintiff statements).  This essentially 
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forced Dr. Ganguly to change the entire direction of her research and she is no longer involved in 
breast cancer research.  Her negative experiences dampened her desire to develop other genetic 
tests for fear of infringing on patents, ultimately taking its toll on patients.  Her case is a prime 
example of the chilling effects of patents (Simoncelli).   
          In the end, the court granted standing to only one plaintiff, Dr. Ostrer, of the twenty 
plaintiffs initially listed.  In law, a party must have sufficient legal interest in the dispute and 
demonstrate harm from the law or action challenged. The court requires standing so it can be 
confident that the dispute will be argued adequately on both sides.  The standing requirement 
prevents citizens from filing frivolous lawsuits.  The court found that most of the plaintiffs did 
not have standing because Myriad had never threatened them with a lawsuit, or they had not 
indicated their actions would change if the Court found in their favor. The court believed the idea 
of having breast cancer survivors as plaintiffs was absurd (Hansen). Even though Myriad had 
clearly threatened to sue Dr. Ganguly, she was not granted standing because she could not 
honestly say she would resume BRCA testing if the courts dissolved Myriad’s patents. Dr. 
Ganguly had already changed directions and her lab was no longer set up for BRCA research. On 
the other hand, when the court posed this question to Dr. Ostrer, he stated he would resume his 
research and testing on BRCA genes (Simoncelli).   
           The ACLU knew it faced an uphill battle with legal standing for its plaintiffs because 
standing was more restrictive in the context of patents, but it deliberately approached this case 
like a civil rights case and not as a patent case.  According to Hansen, if this had been a First, 
Fourth, or Fourteenth Amendment case or a Title VI case (one of the federal civil rights statutes), 
then all of the ACLU’s clients would have been granted standing.  When the ACLU first filed the 
case, many patent bloggers from the Patent Bar predicted it would lose on standing and the court 
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would never get to the merits of the issue.  Even though the Supreme Court decided several years 
before that standing rules in patent cases should be the same as standing rules in other cases (for 
example, First Amendment cases), the Federal Circuit did not follow this ruling. Hansen believes 
the Federal Circuit Court would have liked to have thrown out the ACLU’s only plaintiff who 
was found to have standing, but the court was more interested in defeating them on the merits of 
the case.  He maintains, “They were so eager to express their view that patents were patentable 
that they bent their own, even more restrictive standing rules in order to rule against us on merit” 
(Hansen). 
 
VI. Federal District Court of the Southern District of New York 
The ACLU filed the case in the Federal District Court of the Southern District of New 
York.  Judge Robert W. Sweet was appointed to be a District Court Judge in 1978 and was the 
judge assigned to the case.  By coincidence, Judge Sweet’s law clerk, Herman Yue, received his 
Ph.D. in Molecular Biology from Berkeley.  Yue was a geneticist as well as a lawyer so he 
understood the implications of the science and turned out to be invaluable to Judge Sweet. Yue 
had even once applied for a patent himself.  Judge Sweet confirmed that the case was assigned to 
him on a completely random basis, based upon a computer algorithm (Sweet).  
In March 2010, Judge Sweet and the U.S. District Court struck down Myriad’s patents on 
BRCA genes.  Judge Sweet, in his opinion, declared “DNA’s existence in an ‘isolated’ form 
alters neither this fundamental quality of DNA as it exists in the body, nor the information it 
encodes.  Therefore, the patents at issue directed to ‘isolated DNA’ containing sequences found 
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in nature are unsustainable as a matter of law and are deemed unpatentable under 35 
U.S.C.§101” (S.D.N.Y. March 29, 2010 District Court Opinion).  
Judge Sweet later declared that this case was one of the most challenging and meaningful 
cases he has heard; he believed from the beginning there was a real possibility the case would 
make it to the Supreme Court. Judge Sweet attended the Supreme Court proceedings and was 
very pleased with the outcome of the case.  He thought that the underlying issue, although he did 
not deal with it in his opinion, was how best to advance scientific knowledge.  “Does scientific 
knowledge advance best through a process such as patenting or does it advance best through the 
free exchange of information?”  Judge Sweet also used the case to overturn the legal doctrine 
established in the 1911 decision of Parke-Davis v Mulford, in which Judge Learned Hand 
allowed the patenting of biological substances isolated from nature (Sweet).   
When the ACLU filed the case in district court, it sued both Myriad and the U.S. 
government. Chris Hansen felt that at some level, it was not fair to just sue Myriad.  Myriad had 
applied for and been granted a patent by the federal government; therefore, Myriad was simply 
exercising the authority the federal government had given it.  The ACLU did not realize how 
unusual it was to sue the government to invalidate a federal patent.  In fact, no one had ever done 
it. From the perspective of a civil rights lawyer, it seemed perfectly logical to sue the 
governmental entity charged with a wrong. However, that is not the way patent law has 
customarily been adjudicated in court. This brought controversy and caused ripples in the Patent 
Bar.  A patent blogger actually called for the ACLU legal team to be disbarred for filing such a 
frivolous case.  Ultimately, the District Court dismissed the USPTO, not because it was wrongly 
sued but because it was unnecessary to the case.  The court did not need the involvement of the 
patent office for it to invalidate these patents (Hansen).  
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VII. Federal Circuit Appeals Court 
All patent case appeals must go to the Court of Appeals for the Federal Circuit, 
established by Congress in 1982.  The theory is that patent law is too complicated for those 
without a scientific background so the government established a specialized court with judges 
who can understand the science.  However, the District Court with Judge Sweet and his 
geneticist law clerk appear to have understood the issues at least as well, if not better than the 
Court of Appeals did. As expected, Myriad appealed the case to the Federal Circuit Court 
(Hansen).   
           In July 2011, the United States Court of Appeals for the Federal Circuit upheld 
Myriad’s patents, declaring that human genes are, in fact, patentable.  Judge Alan Lourie wrote 
in his majority opinion, “The isolated DNA molecules before us are not found in nature.  They 
are obtained in the laboratory and are man-made, the product of human ingenuity” (Association 
for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F. 3d 1329 Fed. Cir.2011). 
The ACLU expected to lose the case in Federal Circuit Court because of the long entrenched 
pro-patent stance of the court.  It lost 2-1.  Chris Hansen, however, points out that in his eyes 
they actually lost 1.51 – 1.49.  Judge William Bryson ruled for ACLU on the central issue of the 
case - the patentability of human genes, on the basis that “the genetic coding material …is the 
same, structurally and functionally, in both the native (BRCA) gene and the isolated 
form of the gene” (Association for Molecular Pathology V. U.S. Patent & Trademark 
Office, 653 F. 3d 1329 Fed. Cir.2011). Judge Lourie, a prior chemist put on the court because 
of his expertise, ruled against ACLU on the patentability of human genes.  Hansen paraphrases 
Judge Lourie’s comments, “The question of whether human genes are patentable or not is purely 
a question of chemistry.  Biology is irrelevant” (Hansen).  Chris Hansen believes the absurdity of 
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that statement actually helped ACLU when the case was heard before the Supreme Court 
because it illustrated how one can become caught up and trapped in his or her own expertise.  
The first question Judge Lourie asked during oral argument was, “Isn’t it true that when a gene is 
isolated, you break a covalent bond?”  Chris Hansen related this story at the November 2013 
Science, Technology, and Society symposium at Harvard University.  At that point, Hansen 
maintained that he had learned a fair amount of genetics over the three years that the ACLU was 
putting the case together, but he had no idea what a covalent bond was.  He conceded he “bluffed 
his way through it.”  The opinion of the third judge in the Federal Circuit Court, Judge Kimberly 
Moore, was the reason Hansen professes that ACLU actually lost 1.51 – 1.49.  This judge 
indicated that she did not regard human genes as patentable, but since the USPTO had been 
allowing gene patenting for over twenty years, she was going to “let it slide.”  Judge Moore 
preferred to remain with the status quo due to the huge investments by the biotechnology 
industry that rested on patents.  Hansen was so incensed by Moore’s comment that he jokingly 
told his colleagues that he wanted to include in his brief, “Well, we had racially segregated 
schools for forty years and we didn’t just let that slide!” (Hansen) 
The ACLU lost on the issue of including the federal government as part of the lawsuit 
when the District Court severed the USPTO from the case.  It did not matter in the District Court 
because Judge Sweet invalidated the patents and the court did not need the patent office to be a 
part of the lawsuit.   The ACLU was then faced with another decision that could make or break 
the entire initiative – should the ACLU appeal the decision to dismiss the federal government 
from the case?  The ACLU decided not to cross appeal. This worked to the ACLU’s favor 
shortly after that when the U.S. government switched sides between the time the case left the 
District Court and went to the Court of Appeals.  When the case got to the Federal Circuit Court, 
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the Solicitor General, the federal government’s highest ranking litigator, indicated that the U.S. 
government’s position was that genes should not be patentable.  Chris Hansen speculates that 
Francis Collins, the head of the National Institutes of Health (NIH) may have played a 
substantial role in turning around the government’s position.  Francis Collins had been publicly 
opposed to gene patents for years.  Undeterred, however, the USPTO continued to issue patents 
on human genes and made it known that it disagreed with the federal government’s position 
(Hansen).    
     Despite the fact that the government switched sides for the case in the Federal Circuit 
Court, the court upheld Myriad’s patent claims on DNA molecules. The ACLU decided to appeal 
to the United States Supreme Court.  The Supreme Court vacated the Court of Appeals’ finding 
in March 2012, and remanded the case back to the Federal Circuit, instructing the Court of 
Appeals to reconsider the ruling taking into account the Mayo Collaborative Services v. 
Prometheus Laboratories decision that the Supreme Court had announced the prior week.  In 
Mayo, the Supreme Court unanimously struck down a medical diagnostics patent covering the 
relationship between drug dosing and levels of specific metabolites in the blood.  Justice Stephen 
Breyer, in speaking for the Court, held that the relationship between drug doses and metabolites 
was “not patentable because it constituted a law of nature” (Mayo Collaborative Services v. 
Prometheus Laboratories, Inc., 566 U.S_132 S. Ct. 1289 2012).  When the Court of Appeals 
reconsidered the Myriad case in light of Mayo, the same three judges on August 16, 2012 once 
again ruled 2-1 upholding Myriad’s claims on DNA molecules, stating that isolated DNA is, in 
fact, patentable.  (The court also unanimously upheld one method claim on using BRCA assays in 
discovering drugs to treat cancer and invalidated five broad method claims for detecting 
mutations in BRCA genes).  
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VIII. United States Supreme Court 
          By the time the Myriad case wound its way to the Supreme Court, many predicted the 
ACLU might win; however, this was not always the case.  Early on, most researchers and 
medical geneticists predicted the ACLU would not stand a chance of winning such a case.  A 
majority of legal scholars were supportive in the sense that they agreed that gene patenting was a 
relevant issue and that patents on human genes were wrong as a matter of law and policy.  
However, these same scholars believed the chances of winning a legal challenge in this arena 
were infinitesimal (Hansen).  The United States Patent and Trademark Office (USPTO) had been 
issuing gene patents since the late 1970s, the biotech industry had grown up around this practice, 
and the Patent Bar was committed to maintaining the status quo.  Several had tried and failed to 
challenge this policy through a formal comment process with the USPTO back in the early 
2000s, when patent examination guidelines for utility and for written description were being 
revised.  Legislation to end gene patenting had been introduced and gone nowhere.  Medical 
researchers had dealt with the headaches of gene patents for so long that they assumed gene 
patenting was too entrenched to change (Simoncelli).  Hansen was undeterred with the naysayers 
and negativity because he maintained all along that gene patenting was wrong.  Simoncelli and 
Hansen did discuss whether or not they were going to actually make the law worse if they lost 
the case, but decided the risk was minimal because the law could not get much worse. They were 
passionate about taking the case on to challenge gene patenting (Simoncelli).  It was fortunate 
that the ACLU remained steadfast in its commitment because there were not many organizations 
that could have developed the case the way the ACLU did.  
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Simoncelli herself initially thought the odds of winning the case were under fifty percent, 
although Hansen was more optimistic.  Simoncelli envisioned they would more than likely lose 
due to long-standing deference to the USPTO; there was a precedent of more than twenty years 
of allowing these patents.  Nevertheless, in Simoncelli’s mind, “even if they lost the case, they 
could win.”  Despite the uphill battle they faced, she felt it was essential to bring the issue of 
gene patenting to the forefront (Simoncelli). 
The Supreme Court accepts approximately one percent of the cases before it, but the 
ACLU anticipated that it was likely it would hear this case.  The case had appeal because it dealt 
with breast cancer and the human body.   When drafting the “question presented” to go before 
the Supreme Court, the ACLU made a deliberate choice to simplify the question down to four 
words. According to Chris Hansen, typical questions go along the lines of, “Given the position of 
the Federal Circuit in Smith V. Jones, in the absence of…, and the alternatives of…”   Lawyers 
typically want to spin the question presented.  The ACLU elected to present one of the shortest 
questions ever presented: “Are human genes patentable?”  Four words!  Hansen and Simonceilli 
strategically simplified the question because intuitively they felt that if the Supreme Court 
thought about the case the way Tania Simoncelli first presented it to Hansen, they would 
ultimately prevail.  They wanted the Supreme Court to consider the case from a common sense 
point of view rather than strictly from the viewpoint of patent law or genetics (Hansen).  
The ACLU petitioned for certiorari on the standing issue when the case went to the 
Supreme Court, but that part of its petition was not granted.  The organization decided to add the 
standing question for political reasons.  Hansen had been offended that the lower court had not 
granted the plaintiffs standing, and contended that it was contrary to the Supreme Court’s 
decision several years ago on standing in patent cases.  In addition, he did not want the case to be 
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called Ostrer v. Myriad.  He vowed to take the case to the Supreme Court with every single 
plaintiff still attached to it.  If they had petitioned for certiorari without the standing question, 
then they likely would have had to re-title the case and Hansen was not willing to do that.  There 
was important symbolism in making sure the Supreme Court knew who all the plaintiffs were, 
even if only one of them had been granted standing (Hansen). 
           By the time of the oral arguments, Chris Hansen had retired from the ACLU and Tania 
Simoncelli had left the ACLU to take a position with the FDA.  Hansen came back out of 
retirement and Simoncelli took a leave of absence from her job to prepare for the Supreme Court 
case (Hansen and Simoncelli).  Hansen had been approached by many lawyers offering to take 
over the oral arguments for him, but there was no way he was going to give up presenting the 
oral argument (Hansen).  
           The team invested a great deal of time on the briefs.  Hansen is a firm believer that the 
brief should be a coherent narrative and sound like it is authored by one voice.  He spent most of 
the time explaining genetics and what a gene was and how isolating a gene does not turn it into 
something else.  His team also resurrected all the metaphors that they used in the lower courts 
and these turned out to be central to the case.   Hansen’s favorite metaphor related genes to gold.  
He declared, “If you take gold out of a mountain or stream, it is still gold.  You have not 
transformed it.  It is true that once you take it out of the mountain, you can use it in jewelry, so 
there is a new potential use for the gold. And it is true that inside the mountain gold does 
something different from what it does outside the mountain.  Inside the mountain, it is helping to 
hold up the mountain; however, that doesn’t make it patentable.”  The only problem with this 
metaphor is that gold is not a part of the body.   When brainstorming human body metaphors, the 
team settled on a kidney.  Hansen stressed, “Isolating DNA is no different from isolating a 
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kidney and no one would suggest that isolating a kidney was patentable.  It is true that you can 
take it out of the body and put it in someone else’s.  It has a new use and it is also severed from 
the rest of the body (just as a gene is severed from the chromosome).”  Hanson conceded that 
when he used the kidney metaphor in the Federal Circuit Court, one of the judges exclaimed, “Of 
course, a kidney is not patentable; it’s an organ, not a gene!”  Hansen never understood what he 
meant by that (Hansen STS).  
Hansen went first during the oral arguments for the Supreme Court because the ACLU 
had lost the case in the Federal Circuit Court.  The justices did not ask questions that he had not 
anticipated and it went relatively well.  Hansen maintains the most interesting part was his 
opponent’s response when Justice Kagan asked, “I understand that you believe a gene is 
patentable, is that correct?”  Gregory Castanias, the lead attorney representing Myriad Genetics 
replied, “Yes.”  Justice Kagan then inquired, “Well is an entire chromosome patentable?” 
Castanias responded, “Well, that presents a different question.  It may violate other aspects of the 
patent law, and, for example, you would have to consider…”  Justice Kagan cut him off.  “You 
are not answering my question.”  (He was violating the tenet that the first answer when asked a 
“yes/no” question by a judge, especially a Supreme Court Justice, is a “yes” or “no”).  Finally, 
when pressed enough, the attorney asserted, “Yes, a chromosome is patentable.”  “So,” Justice 
Kagan inquired, “is a kidney patentable?”  He stammered, “Well, that depends on a lot of issues 
of patent law….,” and she cut him off as he tried to duck the question.  Finally, he shot back, 
“Yes, a kidney is patentable!”  At that moment, Hansen sensed victory (Hansen STS).   
The case was decided 9 - 0 in their favor, a unanimous decision.  Justice Clarence 
Thomas, in writing for the court, noted, “A naturally occurring DNA segment is a product of 
nature and not patent eligible merely because it has been isolated.  It is an undisputed fact that 
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Myriad did not create or alter any of the genetic information encoded in the BRCA1 and BRCA2 
gene.  Groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the 
criteria for patent eligibility” (Association for Molecular Pathology et al v. Myriad Genetics, Inc. 
et al, No. 12-398, U.S. 2013).                                  
During the oral arguments, protesters gathered outside the Supreme Court to demonstrate 
their opposition to gene patenting, holding signs, “Your corporate greed is killing my friends” 
and “My genes are not your property.”  This case resonated strongly with the public as it had 
implications for the lives of millions of women. Breast cancer is an emotional topic and many 
individuals were gripped by the potential outcome of the case.  The actress Angelina Jolie 
brought additional national attention to BRCA genes and the breast cancer cause when, during 
the Supreme Court case, she publicly announced in a May 14, 2013 op-ed piece in the New York 
Times that she had undergone a prophylactic double mastectomy after learning that she had 
tested positive for a BRCA mutation.  Her editorial also brought attention to the fact that the cost 
of the BRCA test remained an obstacle for many women (Jolie 2013).  The ACLU had declared 
all along that this was a case about civil rights and a case about real women; the outpouring of 
public interest in the case substantiated this.    
 Looking back, Chris Hansen related a few interesting points about the Supreme Court 
decision in Harvard’s 2013 Science, Technology, and Society (STS) symposium. First, “it was 
not the Supreme Court’s best work.” (Hansen).  Although the ACLU won the case with a 
unanimous decision, the decision does not give enough guidance to the lower courts about when 
something is or is not patentable.  In previous decisions, the Supreme Court has given better 
guidance.  Hansen noted that the Justices may have believed it was “patently obvious,” so they 
did not need to define clear rules.  Second, the Supreme Court declared that cDNA is patentable.  
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He suspects the ACLU won on genomic DNA (that is not patentable) because it seemed self-
evident.  He concedes they may have lost on cDNA (the Court determined that it is patent 
eligible) in part because both the government and Dr. Eric Lander from Harvard submitted briefs 
stating cDNA should be patentable, and that hurt their case.  He emphasizes, “It is too soon to 
know how much the cDNA issue will matter as other patent law doctrines could well knock out 
the patentability of cDNA.” Many scientists maintain there is a way to get around cDNA claims.  
According to Hanson, “It could be a harmless loss” (Hansen).  
 
IX. Why did the ACLU prevail? 
Hansen and Simoncelli are extremely proud of the fact that even though most predicted 
they would never succeed in a gene patenting case, they not only took this case all the way to the 
U.S. Supreme Court, but won decisively 9-0. Working with scientists is challenging for lawyers 
as most lawyers, according to Hansen, are not comfortable discussing science.  It seemed 
incomprehensible to Hansen when he started this case that he would ever understand any part of 
genetics (Hansen), but he dedicated himself to learning all he could and became quite competent 
(Simoncelli).  It was an incredibly rewarding experience for both Hansen and Simoncelli who 
were passionate about this case because it mattered to so many people.  Their strength was in 
building a coalition because bringing a case like this to the Supreme Court is a collective effort, 
not the work of one person.  Including diverse perspectives made their argument stronger 
(Hansen and Simoncelli).  
Simoncelli and Hansen feel that ultimately they were able to reverse over twenty years of 
patent law precedent because they framed this case so broadly.  At the heart of this case was a 
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relatively straightforward legal question:  is isolated DNA patent-eligible under section 101 of 
the Patent Act?  They intentionally did not limit their arguments strictly to this sphere.  They 
sought to include a range of arguments as to the impacts that gene patents were having on 
research, data sharing, clinical practice, patient experience, and access to care.  They viewed 
litigation as a vehicle for bringing to the forefront a comprehensive understanding of how 
improperly issued patents can actually harm people and stand in the way of innovation. The 
coalition of experts and plaintiffs that they assembled for the case reflected this broad framing.  
The plaintiffs included not only the geneticists who received cease-and-desist letters from 
Myriad Genetics, but genetic counselors who would have liked to provide their patients with 
more and better testing options, as well as individual women who were unable to access testing 
or were interested in a second opinion.  They sought and obtained declarations not only from 
geneticists who could explain what was meant by isolating DNA, but also, for example, from Dr. 
Mary-Claire King from the University of Washington who originally demonstrated the existence 
of BRCA1 by discovering linkage between markers on chromosome 17 and risk of breast cancer 
in 1990 (Simoncelli).  Dr. King later described the high incidence of false negative results (12%) 
that were the result of Myriad’s refusal to update its test for a period of several years (Walsh).  
An STS scholar provided a detailed account of the history of the discovery of the BRCA genes to 
make clear that Myriad did not deserve credit as the sole discoverer of these genes (Simoncelli).  
The Nobel Prize winning economist, Joseph Stiglitz, described gene patents as a classic example 
of how the social cost of patenting that arises from the restrictions of the use of knowledge and 
the granting of monopoly power can outweigh any benefits that arise from public disclosure. 
Stiglitz argued, “These are patents on basic scientific knowledge- the very instructions inside 
each of our cells that determine what proteins are produced…In the case of a genetic sequence, 
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one cannot build upon the knowledge without having ‘access’ to the genetic sequence” (Sticklitz, 
Declaration to U.S. District Court for the Southern District of New York).  
The U.S. Supreme Court opinion actually said nothing about the broader implications of 
public gene patents, research, access to testing, or patient care.  However, Simoncelli argues that 
the case would never have made it to the Supreme Court if ACLU had not framed the issue as 
broadly as it did.  The stage was set for the case in the U.S. District Court, and Judge Sweet 
described in his opinion the full range of public health concerns with regard to gene patenting.  
Also, because the ACLU framed the case broadly, it attracted an even wider range of 
stakeholders who joined as amici in the case.   The amici included such diverse groups as 
medical associations and patient advocacy groups, environmental organizations, religious 
groups, and even some genetic diagnostic companies who chose to break away from the biotech 
industry’s line on the issue.  Simoncelli suspects that the broad framing of the case may have 
also influenced the U.S. government’s decision to engage agencies other than the USPTO in its 
internal deliberations that resulted in the government switching sides in the case.  The 
government changing sides was a pivotal moment in the case.  The U.S. government’s brief in 
the Federal Circuit specifically noted that the issue before the court turned on questions that 
implicate the expertise and responsibilities of a wide range of federal components, including not 
only the USPTO, but also the National Institute of Health (NIH), the anti-trust division of the 
Department of Justice (DOJ), the Centers for Disease Control (CDC), the Office of Science and 
Technology Policy (OSTP), the National Economic Council, and others (Simoncelli).   
Another reason the ACLU ultimately prevailed, according to Tania Simoncelli, is that the 
team was able to adequately explain the scientific principles in the case. They needed to figure 
out how to explain enough of the science to make clear why the claims it was challenging were 
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so fundamentally wrong.  The plaintiffs had to explain in simple terms what a gene is; what 
DNA is; what isolated DNA is; why is it isolated; why is isolated DNA virtually the same 
structurally and functionally as DNA in the body; why a patent on isolated DNA is going to, in 
effect, be a patent on the DNA itself; what Myriad did and did not do; and why what Myriad did 
is not an invention. It was a balancing act to explain these core arguments without adding “fuel 
to Myriad’s attempt to make it all seem so complicated that it should be viewed as beyond the 
court’s ability to decide it” (Simoncelli).  That balancing act required experts and plaintiffs who 
were clear communicators, who were teachers of science with sufficient patience to work with 
the ACLU on this.  It also required a commitment of the scientists and attorneys to understand 
one another.  The experts devoted an extraordinary amount of time to work through these issues 
(Simoncelli). 
The law, timing, and luck were also reasons why the ACLU and the other plaintiffs 
prevailed, according to Simoncelli.  The law was truly on their side and they had a small team of 
lawyers who made it clear to the court that Myriad, in fact, did not invent anything, and that 
DNA in its isolated form is just as much a product of nature as the DNA in our bodies.  Timing 
was critical in the sense that science had outpaced policy at that point and the $1,000 genome 
was on the horizon.  That made Myriad’s charge of almost $4,000 for sequencing and 
interpreting just two genes seem exorbitantly expensive.  A number of multi-gene tests were 
entering the market, and researchers had increasing concerns about patents interfering with the 
development of these tests.  Lastly, luck played a key role in that the ACLU filed the case in the 
Southern District of New York and randomly drew Judge Sweet who happened to have a clerk 
with a Ph.D. in molecular biology.  The odds of drawing a judge who happened to have a law 
clerk with a scientific background in this field were extremely low.  Judge Sweet took a keen 
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interest in the case and wrote a scientifically accurate and well-reasoned 153 page opinion, 
setting the stage for the ACLU’s argument in the best possible way.  This played a significant 
role in the outcome of the case (Simoncelli) and Judge Sweet later sat in the front row to watch 
the Supreme Court proceedings (Sweet).    
 Eight years elapsed between the time Simoncelli first brought up gene patenting with 
Hanson and the ruling by the Supreme Court.  It was an enormous financial and emotional 
investment by scores of people.  That investment led to several important legacies, perhaps none 
more important than raising the consciousness of the public as to the importance of the life 
sciences and the field of genetics in our everyday lives. The ACLU’s ability to humanize the 
gene patenting issue took the debate out of the scientific arena and put it squarely into the public 
arena.  The ACLU maintained all along that this issue mattered to real people and that individual 
genes, our genetic heritage, should not be owned by a corporation. This campaign is a shining 
example of how the public can be engaged in the debate of a scientific issue, even without 
knowing much about the science behind the issue. The lawsuit reminded all that our civil 
liberties must be given equal priority as science continues to develop new and exciting 
capabilities.  Finally, the case reminds us that there are avenues for addressing the thorny issues 
that accompany any exciting new discovery and that these avenues can work, even against the 
longest of odds. 
 
  
 
 
 
41	  
	  
 
 
 Possible Future Interviews: 
 
Justice Kagan, United States Supreme Court 
Dr. Francis Collins, Director of the NIH 
Dr. Eric Lander, Founding Director of the Broad Institute 
Myriad Genetics lawyers Brian Poissant, Laura Corruzi, and Gregory Castanias 
Chris Mason, Assistant Professor of Physiology and Biophysics at Weill Cornell Medical   
          College (May 2, 2014) 
 Randal Rader, Chief Justice of the Court of Appeals for the Federal Circuit  
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